Tham khảo tài liệu 'báo cáo hóa học: " the state of the art of adeno-associated virus-based vectors in gene therapy"', luận văn - báo cáo phục vụ nhu cầu học tập, nghiên cứu và làm việc hiệu quả | Virology Journal BioMed Central Review Open Access The state of the art of adeno-associated virus-based vectors in gene therapy Renata dos Santos Coura and Nance Beyer Nardi Address Department of Genetics Universidade Federal do Rio Grande do Sul Av Bento Goncalves 9500 91501-970 Porto Alegre RS Brazil Email Renata dos Santos Coura - rscoura@ Nance Beyer Nardi - nardi@ Corresponding author Published 16 October 2007 Received 29 August 2007 Accepted 16 October 2007 Virology Journal 2007 4 99 doi 1743-422X-4-99 This article is available from http content 4 1 99 2007 Coura and Nardi licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract The adeno-associated virus AAV has rapidly gained popularity in gene therapy since the establishment of the first AAV2 infectious clone in 1982 due to some of their distinguishing characteristics such as lack of pathogenicity wide range of infectivity and ability to establish longterm transgene expression. Notably over the past decade this virus has attracted considerable interest as a gene therapy vector and about 85 of the currently available 2 041 PubMed references on adeno-associated viruses have been published during this time. The exponential progress of AAV-based vectors has been made possible by the advances in the knowledge of the virology and biology of this virus which allows great improvement in AAV vectors construction and a better comprehension of their operation. Moreover with the recent discovery of novel AAV serotypes there is virtually one preferred serotype for nearly every organ or tissue to target. Thus AAV-based vectors have been successfully overcoming the main gene therapy challenges such as transgene maintenance safety and .
